Introduction
Myocardial infarction is caused by the sudden loss of oxygen and nutrient supply leading to cardiomyocyte death. In addition to the oxygen deprivation induced cardiac cell death, the inflammatory cascades that are particularly induced by ischemia and reperfusion appear to play a key role for the acute injury and the post-infarction repair process 1 .
MicroRNAs (miRNAs, miRs) are small non-coding RNAs that bind to specific target mRNAs and thereby induce degradation or translational repression. Ischemia alters the expression pattern of microRNAs in the cardiac tissue 2 3 , raising the possibility that miRNAs causally affect cardiac function after myocardial infarction (for review see 4 ). Moreover, apoptosis of cardiomyocytes was induced by miR-15 5 or inhibited by miR-24 6 and miR-494 7 .
Furthermore, several miRNAs were shown to regulate fibrosis after myocardial infarction. The up-regulation of miR-21 was linked to cardiac fibrosis by some but not all studies 8, 9 , whereas miR-101 was recently shown to suppress cardiac fibrosis 10 . In addition, members of the miR-17-92 cluster regulated neovascularization after ischemia 3, 11 . Particularly, antagomirs against miR92a improved neovascularization and augmented functional recovery in a murine model of chronic ligation of the left anterior descending coronary artery 3 . Despite these encouraging results from studies in small animals, only limited information is available regarding the preclinical development of miRNA therapeutics for cardiovascular diseases 12 . Locked nucleic acid (LNA)-based inhibitors directed against miR-122 were developed for the treatment of hepatitis C and were shown to be safe and effective in non-human primates and phase II clinical trials 13 . In contrast, evidence of therapeutic efficacy of miRNA inhibitors in ischemic cardiac disease, where timing and delivery venues are of paramount relevance, is lacking in preclinical large animal studies.
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5 region of miR-92a (base 2-17: 5`-CAGGCCGGGACAAGUGCAAUA-3`) and were synthesized as a mixer of LNA and DNA. The LNA control oligonucleotide consists of a sequence directed against a Caenorhabditis elegans-specific miRNA with a comparable LNA/DNA content.
AntimiR and control oligonucleotides were dissolved in PBS before administration.
AntimiRs were applied either systemically (i.v., "LNA-92a iv"), or regionally antegrade ("LNA92a ante") into left anterior descending (LAD) artery or retrograde ("LNA-92a retro") into the anterior interventricular vein 5 min before reopening of the infarct vessel (0.03 mg/kg body weight).
Hemodynamic Measurements
Left ventricular enddiastolic pressure (LVEDP) and ejection fraction measurements were performed before ischemia and after 72 hours or 7 days of reperfusion. Additionally, regional myocardial function was obtained after 72 hours or 7 days of reperfusion.
Infarct size
Infarct size was assessed via methylen blue exclusion, tetrazolium red viability staining as described earlier 15 .
Histological analysis
Myeloperoxidase assays were performed for evaluation of leukocyte influx in the ischemic area as described 15 . Capillary density (PECAM-1 staining) as well as cell death (TUNEL staining) was analyzed in the ischemic border zone. (cf. supplementary methods)
RNA isolation, real-time PCR and immunoblotting
Real-time PCR and western blot were conducted according to standard protocols. (cf.
supplementary methods)
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Generation of miR-92a deficient mice
The constitutive and conditional deletion of miR-92a-1, which is expressed by the miR-17-92a
cluster, was generated by homologous recombination in 129Sv/Pas embryonic stem (ES) cells by genOway (Lyon, France). For this purpose a targeting vector containing the homologous genomic miR-92a-1 sequences flanked by loxP sites and a neomycin gene flanked by FRT sites was used. For the generation of constitutive miR-92a deficient mice (miR-92a -/-) the miR-92a recombined chimeric mice were bred with a deleter line constitutively expressing the Cre recombinase. For the generation of conditional cardiomyocyte-specific miR-92a knockout mice (miR-92a fl/fl, MHC-Cre) the miR-92a recombined chimeric mice were first bred with C57BL/6J wild type and Flp recombinase expressing deleter mice to excise the neomycin selection cassette and then mated with a Cre deleter line expressing Cre recombinase under the control of the MHC-Cre promotor.
Myocardial infarction in mice
Acute myocardial infarction (AMI) was induced by permanent ligation of the left anterior coronary artery as previously described 16 . Cardiac function was determined by high resolution echocardiography 16 .
Cell culture experiments
Cell death was induced in HL-1 cardiomyocytes by 18h hypoxia/ 4h reoxygenation in the presence of LNA-92a or LNA-Co. Leukocyte adhesion on HUVEC monolayer under flow (1 dyne/cm 2 ) were performed with the iBidi system after 15 ng/ml TNF stimulation (cf.
supplementary methods).
Statistical Analysis
The results are given as mean values ± SEM. Statistical analysis were performed via one way C57BL/6J wild type and Flp recombinase expressing deleter mice to excise the n ne neom om myc yc ycin in n election cassette and then mated with a Cre deleter line expressing Cre recombinase under the co ont nt ntro ro rol l l of of of t t the he he MH MH MHC-C Cre promotor.
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Results

Inhibition of miR-92a by systemic versus local delivery of LNA-92a
First, we assessed the inhibitory potential of LNA-92a. Due to conservation of the miR-92a
sequence between mouse and pig, we used the same sequence as described previously 3 . For this purpose, we applied LNA-92a either systemically (by intravenous infusion) or via catheter-based antegrade or retrograde local delivery to the heart. We infused 5 mg/kg heart weight based on pilot studies in mice (data not shown). miR-92a expression 72 h after I/R was reduced by LNA- purpose, we applied LNA-92a either systemically (by intravenous infusion) or v via ia a c c ca athe he hete te ter-r-r-ba b base s d
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In summary, these data demonstrate that both local catheter-based delivery as well as i.v.
delivery of LNA-92a reduced cardiac miR-92a expression. The concomitant miR-92a-repression in other tissues such as the lungs was ameliorated by local LNA-92a delivery. However, when increasing the dose, antegrade delivery also fully repressed miR-92a expression in all tested organs.
Catheter-based delivery of LNA-92a decreases infarct size and apoptosis in the heart
To assess the cardioprotective effect of LNA-92a, we measured infarct size ( Figure 3A/B) .
Analysis of the primary ischemic region (area at risk) revealed no differences between the control and treatment groups ( Figure 3C ). Intravenous application of LNA-92a did not significantly decrease infarct size compared to control groups, whereas antegrade and retrograde application of LNA-92a significantly reduced infarct size to 32+5% and 36+4% of the area at expression of miR-92a appeared unaltered after antegrade and retrograde LNA-9 92a 2a 2a app pp ppli li ica ca cati ti tion on, , and was found reduced after i.v. LNA-92a-infusion and by antegrade delivery of the higher co onc nc ncen en ent tr trat at atio io ion n n of f L L LN NA N -92a ( Figure 2D ).
In sum mma ma ary y y, th th thes s se e da da data ta ta d dem em mo on onst str r rate th h hat b b bot th lo lo oc ca cal l ca ca ath the e ete er r-b bas as sed d d del e eli iv iver ery y y a as as w w wel el ell l l as as s i i i.v. Figure 3A /B). Similar effects were seen when infarct size was determined 7 days after ischemia/reperfusion (Supplementary Figure   3A) . Next, we analyzed the effect of LNA-92a on cell death as measured by TUNEL assay.
Systemic i.v. application of LNA-92a did not reduce cell death in the ischemic area. However, local application via retrograde or antegrade delivery of LNA-92a significantly reduced cell death in comparison to the control groups ( Figure 3D,E) . Even the higher dose of LNA-92a had no additional effect compared to the standard dose of LNA-92a (5 mg/kg heart weight, Figure   3D /E).
miR-92a inhibition improves global and regional myocardial function
Next, we were interested in analyzing the effect of LNA-92a on heart function. Table 1 ). Analysis of hyokinetic and akinetic segments in the left ventricular angiography showed a significant reduction particularly after antegrade delivery of LNA-92a compared to controls and systemic
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Consistently, analysis of regional myocardial function showed an enhanced regional contractility after LNA-92a application under pacing. Catheter-based local application of the LNA-92a resulted in a significantly improved functional reserve of the ischemic region (at rapid atrial pacing) when compared to controls or intravenous LNA-92a application ( Figure 4E , Supplementary Figure 3D ).
Inhibition of miR-92a increases capillary density
Previous studies demonstrated that inhibition of miR-92a increased angiogenesis in mice after myocardial ischemia induced by chronic ligation of the coronary artery 3 . Therefore, we determined whether LNA-92a treatment also affects neovascularization after ischemia/reperfusion in pigs. Indeed, catheter-based delivery of LNA-92a but not i.v. application 
Inhibition of miR-92a reduces cardiac inflammation
A main effector of ischemia/reperfusion injury is overwhelming postischemic inflammation.
Therefore, we additionally elucidated the effect of LNA-92a on the recruitment of leukocytes to the heart. Catheter-based LNA-92a treatment significantly reduced the number of leukocytes in the infarcted region of the heart by about 50 % compared to the control groups ( Figure suggesting that miR-92a influences the adhesive capacity of both, endothelial cells as well as leukocytes.
Inhibition of miR-92a protects myocytes from hypoxia/reoxygenation-induced cell death
In addition to the vascular and anti-inflammatory effects described above, LNA-92a may act as a direct cardioprotective agent. Therefore, we investigated the influence of LNA-92a on myocyte survival. LNA-92a pre-treatment of cardiomyocytes (HL-1 cells) significantly reduced hypoxia/reoxygenation-induced cell death compared to LNA-Co treated cells ( Figure 7A ).
Further analysis of the cardiomyocyte cell death revealed a decreased apoptosis as well as necrosis after LNA-92a treatment in cells undergoing hypoxia and reoxygenation ( Figure 7B ).
To test whether the direct cardioprotective effect of repressing miR-92a in cardiomyocytes is indeed contributing to the improvement of heart function after acute myocardial infarction, we subjected constitutive miR-92a-/-mice and cardiomyocyte-specific miR-92a deficient mice to acute myocardial infarction (Figure 7C-H Further analys ys ysis is is o o of f f th th t e e e ca c c rd rd dio io iomy my myoc oc o yt yt yte ce ce c ll ll ll d d dea ea eat t th h h re re reve ve veal aled ed ed a a a d d dec ec ecre re reas s sed ed ed a a apo po popt pt ptos os sis is is a a as s we we w ll as t t t indicative of an impairment of cardiac function, whereas miR-92a-/-mice showed a preserved cardiac function after AMI ( Figure 7E ). Cardiac specific deletion of miR-92a resulted in a partial protection of cardiac function after AMI ( Figure 7H) . Moreover, left ventricular ejection fraction was more efficiently reduced in controls (-36±10 %, p<0.05 vs. day 0) compared to MHC-Cre+/-miR-92afl/fl mice (-27±10 %, n.s.) 14 days after infarction. These data demonstrate that constitutive genetic deletion of miR-92a in all cells significantly improves cardiac function, whereas deletion of miR-92a in cardiomyocytes only partially rescues the impaired function after acute myocardial infarction.
Discussion
The data of the present study demonstrate that inhibition of miR-92a by a LNA-based miRNA inhibitor improves the recovery after ischemia/reperfusion in a pig model. In addition, this study provides first evidence that local catheter-based delivery of the LNA-based miR-92a inhibitor more effectively augments the cardioprotective effects than systemic application. LNA-based miRNA inhibitors were tested before in mice and large animal models. For example an inhibitor directed against miR-122 was shown to suppress miR-122 expression in the liver and was successfully tested in a phase II clinical trial for treatment of hepatitis C 13, 17, 18 . In addition,
LNA-based inhibitors directed against miR-15 were shown to effectively block miR-15 expression in the hearts of pigs 5 . These data are consistent with our findings showing a profound inhibition of miR-92a after local delivery of LNA-92a. However, the dosage used in the present study is considerably lower than those used in the previous studies which applied 1 mg/kg body weight LNA-based miR-15 inhibitor in pigs 5 and 10 mg/kg body weight of LNAs to target miR-122 in monkeys 18 . This may explain why i.v. infusion of LNA-92a was not fully effective in
The data of the present study demonstrate that inhibition of miR-92a by a LNA-based miRNA t n nhi hi ibi bi bito to tor r im im impr prov ves es es t the recovery after ischemia/r rep ep epe er rfusion in a pi ig g g mo ode de del. l In addition, this study f f blocking miR-92a expression in the heart. In contrast, local cardiac delivery, which is estimated to deliver 5 mg/kg heart weight (=0.03 mg/kg body weight), effectively blocked miR-92a. The present study provides evidence that local catheter-based delivery more profoundly inhibits miR92a expression in the heart compared to i.v. infusion. Thereby, both antegrade and retrograde infusion had similar effects on miR-92a inhibition in the infarct zone ( Figure 1C ) and on recovery of cardiac function (Figure 4) . However, antegrade delivery was slightly more effective in reducing miR-92a expression in the remote zone ( Figure 1B) . Of note, local cardiac delivery of viral vectors such as adenoviruses 19 and adeno-associated viruses (AAVs) 20 Functionally, the local delivery of antimiRs directed against miR-92a significantly improved the recovery of cardiac function. To our knowledge, this is the first study documenting that inhibition of miRNAs can provide a functional benefit in a large animal model of cardiac ischemia/reperfusion injury. LNA-92a reduced infarct size and augmented cardiac contractile function. Furthermore, capillary density was increased, whereas inflammation was partially suppressed by miR-92a inhibition. The increase in capillary density observed after LNA-92a treatment is consistent with previous studies showing that inhibition of miR-92a improves angiogenesis and neovascularization after hind limb and cardiac ischemia in mice 3 . In accordance, pro-angiogenic factors such as eNOS 21 and thymosin ß4 15 improve cardiac function by limiting the endothelial cell loss and subsequent microcirculatory disturbance in porcine ischemia-reperfusion injury models. The time course of this effect, e.g. 72h of reperfusion after acute ischemia, also argues in favor of a higher grade of preservation of pre-existing capillaries, which are otherwise lost in the course of infarct development.
In addition, suppression of overwhelming inflammation by LNA-92a may limit the amount of cell loss due to the ischemia-reperfusion challenge. Consistently, inhibition of miR- However, the mechanism(s) by which miR-92a inhibitors affect leukocyte adhesion are unknown and deserve further studies.
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Reagents
All chemicals and cell culture media were obtained from Sigma (Taufkirchen, Germany).
Contrast agent Imeron 350 was provided by Bracco Imaging (Konstanz, Germany). LNAmodified antimiRs were kindly provided by miRagen Therapeutics (Boulder, CO, USA).
Pig Ischemia-Reperfusion Model
All pig experiments were conducted at the Walter-Brendel Center for Experimental Medicine at the University of Munich. Pigs (n= 5/experimental group) were instrumented as previously described 1 2 . Briefly, a percutaneous transluminal coronary angioplasty (PTCA) balloon catheter was advanced via guiding catheter and the balloon was placed in the left anterior descending artery (LAD) distal to the first diagonal branch and inflated with 6atm (0.41MPa) for 60 minutes. Correct localization of the coronary occlusion and patency of the first diagonal branch were ensured by injection of contrast agent via guiding catheter. In all groups, the PTCA balloon was deflated after 60 minutes of ischemia; the onset of reperfusion was documented angiographically. After either 72h or 7 days of reperfusion, hemodynamic measurements were performed and the pigs were sacrificed for further analysis of the infarct size, inflammation and apoptosis as described below.
AntimiR Application
AntimiRs were delivered either systemically by intravenous infusion ("LNA-92a iv") or regional delivery, e.g. antegrade ("LNA-92a ante") or retrograde ("LNA-92a retro"). For systemic application, LNA-92a was applied intravenously 5 min before reopening of the occluded vessel (5 mg/kg heart weight = 0.03mg/kg body weight). Local antegrade application was performed via the "over the wire" PTCA balloon catheter (either 5 mg/kg heart weight "LNA-92a ante", or 25 mg/kg heart weight "LNA-92a high ante"). Here the vessel was reopened after 60 min of ischemia, the "over the wire" PTCA balloon was slightly inflated again and the infusion of the LNA-92a ante and LNA-92a high ante was performed for 5 min. Retrograde application was performed via selective pressure-regulated retroinfusion as described earlier 1 2 . Briefly a retroinfusion catheter was introduced to the anterior interventricular vein (AIV) before placement of the LAD occlusion. After 55 min of ischemia selective retroinfusion of 5 mg/kg heart weight LNA-92a was performed for 10 min.
For control, either PBS ("control") or control LNAs ("LNA-Co") were applied by antegrade infusion as described above for the LNA-92a ante group at a concentration of 5 mg/kg heart weight. For 60 min ischemia and 7 days reperfusion a control groups as well a LNA-92a high ante group was performed.
Hemodynamic Measurements
Left ventricular enddiastolic pressure (LVEDP) and ejection fraction (EF) measurements were performed before ischemia and after 72 hours / 7 days of reperfusion. Additionally, regional myocardial function was obtained at 72 hours / 7 days of reperfusion via ultrasound crystals (Sonometrics, USA). Here the ultrasound crystals were implanted in the ischemic and non-ischemic tissue after sternotomy and opening of the pericard. Subendocardial segment shortening (SES) was assessed in the ischemic and non ischemic region at rest and under increased heart rated (150 bpm).
Infarct size
Infarct size was assessed by methylen blue exclusion, tetrazolium red viability staining as described earlier 1 . Briefly, before explantation of the heart the LAD was ligated at the side of infarct induction and methylen blue was injected into the left ventricle. After excision of the heart, tetrazolium red was injected into the LAD distal of the occlusion site, thereby staining the viable myocytes in the ischemic area. Then the heart was cut into 5 slices and digital pictures were taken for planimetric analysis of the infarct size and the area at risk (AAR).
Tissue samples of the infarct area, the AAR and the control region were harvested for TUNEL assay, capillary staining and myeloperoxidase assay. Furthermore, for detecting miR-92a expression, each of the 5 slices was further cut in pieces as representatively shown in Figure 1A .
Histological analysis
Myeloperoxidase assay were performed for evaluation of leukocyte influx in the ischemic are as described before 
RNA isolation and real-time PCR
Tissue samples from infarcted and non-infarcted heart, as well as lung, liver, spleen and kidney were collected, total RNA was isolated with miRNeasy kits from Qiagen following the manufactures protocol and real-time PCR was performed with Applied Biosystems (Carlsbad, CA) microRNA assays for microRNAs on a StepOnePlus device (Applied Biosystems). 
Western blot
Generation of miR-92 deficient mice
The constitutive and conditional miR-92a-1 knockout mouse models were generated by homologous recombination in 129Sv/Pas embryonic stem (ES) cells by genOway (Lyon, France). For this purpose, a targeting vector containing the homologous genomic miR-92a-1 sequences flanked by loxP sites and a neomycin gene flanked by FRT sites was used. The sequence of the microRNA miR-92a exists on two Chromosomes, Chr-13 (human) resp. Chr-14 (mouse) and Chr-X. The sequence on Chr-13 (human) resp. Chr-14 (mouse) was named miR-92a-1 and the one on Chr-X is named miR-92a-2. In the KO mice the predominant miR92a form miR-92a -1 was deleted, whereas miR-92a-2 is still intact. Recombined ES cell clones were injected into C57BL/6J blastocysts. Injected blastocysts were re-implanted into pseudo-pregnant females to generate miR-92a recombined chimeras, which were then used either for generation of constitutive or conditional miR-92a knockout mice.
For the generation of constitutive miR-92a knockout mice (miR-92a -/-), the miR-92a recombined chimeric mice were bred with a deleter line constitutively expressing the Cre recombinase. After backcrossing for at least 5 generations with C57BL/6J wild type mice miR-92a -/-reached a background with >99% C57BL/6J. Wild type littermates were used as controls.
For the generation of conditional miR-92a knockout mice (miR-92a fl/fl, αMHC-Cre), the miR92a recombined chimeric mice were bred with C57BL/6J wild type and Flp recombinase expressing deleter mice to excise the neomycin selection cassette. The generated miR-92a fl/+ mice were backcrossed with C57BL/6J wild type mice for at least 5 generations. miR-92a fl/fl (>99% C57BL/6J) were then mated with a Cre deleter line expressing the Cre recombinase under the control of the αMHC-Cre promotor. The resulting miR-92a fl/fl, αMHC-Cre mice were used as cardiomyocyte conditional knockout mice and miR-92a fl/fl mice were used as controls.
Genotyping:
DNA isolation of tails from offspring derived from mating of miR-92a +/-mice was done using 
Micro-Array:
Transcriptional profiling was performed by ATLAS Biolabs GmbH using GeneChip Mouse 
Leukocyte Adhesion
For detection of leukocyte adhesion shear stress experiments were performed as follows:
Ibidi-slides (ibiTreat VI0.4, Martinsried, Germany) were seeded with HUVEC which were pretreated either with LNA-co or LNA-92a (500nM). After 24h, when cells layer was confluent, HUVECs were stimulated with TNFα (15ng/ml) for 18h. Then leukocytes, THP-1 cell line, were superfused at a concentration of 750000 cells per ml and at a flow rate of 0. 
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